An Extension Study to Monitor Long-Term Safety of LUM-201 Treatment in Children with Idiopathic Growth Hormone Deficiency

Date Added
July 25th, 2023
PRO Number
Pro00130044
Researcher
Deborah Bowlby

List of Studies


Keywords
Pediatrics
Summary

Subjects entering this long-term safety extension (LTSE) study must have successfully participated in a pediatric LUM-201 GHD study through at least the 12-month visit and are eligible for continuation of treatment beyond Month 12, if applicable. Subjects may be enrolled into the LUM-201-02 study, having met all enrollment criteria, following successful completion of 12, 18, or 24 months of treatment in a pediatric LUM-201 GHD study.
Subjects who have met the AHV ≥ 6.7 growth criterion and have continued on treatment beyond the Month 12 visit in the LUM-201-01 trial may transition into the LUM-201-02 trial at Month 18 visit. For these subjects, AHV at Month 24 will be compared to AHV at Month 12, and if it is confirmed to be ≥ 80% of the Month 12 AHV, continued treatment with LUM-201 will be offered.

Institution
MUSC
Recruitment Contact
Terry Headley
843-792-4629
headleyt@musc.edu



-- OR --